# Chee Kay Cheung

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/chee-kay-cheung/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,883 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 29 |
| i10-index | 44 |
| Last Known Institution | University of Leicester |
| OpenAlex ID | https://openalex.org/A5026871566 |
| ORCID iD | 0000-0001-8593-7625 |
| Works | 83 |

## Researcher papers

Showing 12 of 13.

- [Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial](https://scholariq.org/papers/azithromycin-in-patients-admitted-to-hospital-with-covid-19-recovery-a/)
- [Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial](https://scholariq.org/papers/convalescent-plasma-in-patients-admitted-to-hospital-with-covid-19-recovery-a/)
- [Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial](https://scholariq.org/papers/casirivimab-and-imdevimab-in-patients-admitted-to-hospital-with-covid-19/)
- [Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis](https://scholariq.org/papers/baricitinib-in-patients-admitted-to-hospital-with-covid-19-recovery-a-randomised/)
- [Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial](https://scholariq.org/papers/aspirin-in-patients-admitted-to-hospital-with-covid-19-recovery-a-randomised/)
- [Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial](https://scholariq.org/papers/sparsentan-in-patients-with-iga-nephropathy-a-prespecified-interim-analysis-from/)
- [Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy](https://scholariq.org/papers/results-from-part-a-of-the-multi-center-double-blind-randomized-placebo/)
- [Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis](https://scholariq.org/papers/rituximab-as-therapy-to-induce-remission-after-relapse-in-anca-associated/)
- [New insights into the pathogenesis of IgA nephropathy](https://scholariq.org/papers/new-insights-into-the-pathogenesis-of-iga-nephropathy/)
- [An update on the pathogenesis and treatment of IgA nephropathy](https://scholariq.org/papers/an-update-on-the-pathogenesis-and-treatment-of-iga-nephropathy/)
- [The pathogenesis of IgA nephropathy and implications for treatment](https://scholariq.org/papers/the-pathogenesis-of-iga-nephropathy-and-implications-for-treatment/)
- [New Insights into the Pathogenesis and Treatment Strategies in IgA Nephropathy](https://scholariq.org/papers/new-insights-into-the-pathogenesis-and-treatment-strategies-in-iga-nephropathy/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Platelet Disorders and Treatments](https://scholariq.org/topics/platelet-disorders-and-treatments/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)

## Researcher university

- [University of Leicester](https://scholariq.org/institutions/university-of-leicester/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.